195 related articles for article (PubMed ID: 15688075)
1. Macro trends in pharmaceutical innovation.
Cohen FJ
Nat Rev Drug Discov; 2005 Jan; 4(1):78-84. PubMed ID: 15688075
[TBL] [Abstract][Full Text] [Related]
2. Reducing impediments to technology transfer in drug abuse programming.
Brown BS
NIDA Res Monogr; 1995; 155():169-85. PubMed ID: 8594455
[No Abstract] [Full Text] [Related]
3. Profitable and nonprofitable drugs.
Van Woert MH
N Engl J Med; 1978 Apr; 298(16):903-6. PubMed ID: 634333
[No Abstract] [Full Text] [Related]
4. Is pharmaceutical innovation declining?: interpreting measures of pharmaceutical innovation and regulatory impact in the USA, 1950-1980.
Wardell WM; Sheck LE
Ration Drug Ther; 1983 Jan; 17(1):1-7. PubMed ID: 6340163
[No Abstract] [Full Text] [Related]
5. [Current challenges for the pharmaceutical research industry].
Chalchat B
Ann Pharm Fr; 1993; 51(1):16-25. PubMed ID: 8215118
[TBL] [Abstract][Full Text] [Related]
6. Scientists' viewpoints on orphan drug problems and possible solutions.
Van Woert MH
Prog Clin Biol Res; 1983; 127():187-95. PubMed ID: 6351099
[No Abstract] [Full Text] [Related]
7. Innovation and compliance are not diametrically opposed.
Raab GK
Qual Assur; 1994 Mar; 3(1):2-8. PubMed ID: 7804614
[No Abstract] [Full Text] [Related]
8. Reviewing the behavioral science knowledge base on technology transfer. Introduction.
Backer TE; David SL; Soucy G
NIDA Res Monogr; 1995; 155():1-20. PubMed ID: 8594449
[No Abstract] [Full Text] [Related]
9. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development.
Engstrom LO
Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295
[No Abstract] [Full Text] [Related]
10. The drug-potency question.
Walker JM
US Navy Med; 1974 Aug; 64(2):26-30. PubMed ID: 4534296
[No Abstract] [Full Text] [Related]
11. Products in the U.S. pipeline. Pharmaceutical Manufacturers Association.
Biotechnology (N Y); 1991 Oct; 9(10):947-9. PubMed ID: 1367805
[No Abstract] [Full Text] [Related]
12. NIMH-sponsored chemical synthesis program.
Manian AA
Psychopharmacol Bull; 1974 Jan; 10(1):51-60. PubMed ID: 4359843
[No Abstract] [Full Text] [Related]
13. Pharmaceutical research is expensive but well worth the cost.
Mossinghoff GJ
Endocrinology; 1991 Jan; 128(1):3-4. PubMed ID: 1986925
[No Abstract] [Full Text] [Related]
14. Preparation and use of drug master files in the pharmaceutical industry.
Personeus GR; Ascione P
J Parenter Sci Technol; 1981; 35(2):63-9. PubMed ID: 7229835
[No Abstract] [Full Text] [Related]
15. [New drugs used in U.S.A. in 1969].
Ravina A
Presse Med (1893); 1970 Sep; 78(40):1747-8. PubMed ID: 5507168
[No Abstract] [Full Text] [Related]
16. The cost of drugs.
N Z Med J; 1969 Jan; 69(440):33-4. PubMed ID: 4974999
[No Abstract] [Full Text] [Related]
17. The role and value of pharmaceutical marketing.
Levy R
Arch Fam Med; 1994 Apr; 3(4):327-32. PubMed ID: 8012620
[TBL] [Abstract][Full Text] [Related]
18. Medical innovation at the crossroads.
Laubach GD; Gelijns AC
Issues Sci Technol; 1995; 11(3):33-40. PubMed ID: 10141894
[No Abstract] [Full Text] [Related]
19. The intensified drug inspection program: procedures and results.
Clevenger WL
Bull Parenter Drug Assoc; 1969; 23(6):263-8. PubMed ID: 5355888
[No Abstract] [Full Text] [Related]
20. The evolution of new drug legislation.
Kelsey FO
BMQ; 1966 Sep; 17(3):72-81. PubMed ID: 5978212
[No Abstract] [Full Text] [Related]
[Next] [New Search]
